Encouraging Results from Imbruvica in CLL and Small Lymphocytic Lymphoma

Improved survival without disease progression prompted independent reviewers to unblind the study comparing Imbruvica against a placebo, in combination with bendamustine and rituximab.

An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

Pharmacyclics, which recently agreed to be acquired by AbbVie Inc for about $21 billion, said Imbruvica showed a statistically significant improvement in survival without disease progression, the study's main goal.

Imbruvica, which is co-marketed by Pharmacyclics and J&J, is already approved for four cancer indications in the United States.

Link to the Reuters report:

http://reut.rs/1Gijzad